Aura Biosciences, Inc. 8-K

What Happened

• On May 11, 2026, Aura Biosciences, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release furnished as Exhibit 99.1 to a Form 8‑K. The company also updated its corporate presentation for investor meetings, filed as Exhibit 99.2, which includes the company’s cautionary note on forward‑looking statements. The Form 8‑K was signed by CEO Natalie Holles.

Key Details

• Filing date: May 11, 2026 (Form 8‑K; Items 2.02 and 8.01).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Exhibits filed: 99.1 = press release with the quarterly results; 99.2 = updated corporate presentation (includes forward‑looking statements caution).
• Signed by: Natalie Holles, Chief Executive Officer and President.

Why It Matters

• The press release and updated presentation are the primary sources for the company’s reported quarterly performance and any forward‑looking commentary; investors should review those exhibits to see revenue, earnings, cash position, clinical or operational updates, and any guidance or outlook the company provides. Because this Form 8‑K furnishes the materials rather than restating figures in full, the exhibits contain the material details that could affect the company’s stock and investor decisions.